Sangamo Biosciences Receives a New Rating from Cowen & Co.

By Jason Carr

Sangamo Biosciences (NASDAQ: SGMO) received a Buy rating from Cowen & Co. analyst Ritu Baral today. The company’s shares opened today at $15.45.

According to, Baral is a top 100 analyst with an average return of 37.6% and a 56.6% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Global Blood Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sangamo Biosciences with a $18.50 average price target.

See today’s analyst top recommended stocks >>

Based on Sangamo Biosciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $20.19 million. In comparison, last year the company had a GAAP net loss of $12.49 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sangamo Therapeutics, Inc. researches and develops transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II on June 22, 1995 and is headquartered in Richmond, CA.